Assignee: Wyeth Holdings Corporation

Location: Madison, NJ
No. of patents: 90

Number	Title	Issue Date
8153768	Calicheamicin derivative-carrier conjugates Methods for preparing monomeric cytotoxic drug/carrier conjugates with a drug loading significantly higher than in previously reported procedures and with decreased aggregation and low conjugate fraction (LCF) are described. Cytotoxic drug derivative/antibody conjug...	04/10/2012
RE42376	Substituted 3-cyanoquinolines This invention provides compounds of formula I having the structure wherein G1, G2, R1, R4, Z, n, and X are defined in the specification or a pharmaceutically acceptable salt ther...	05/17/2011
7915266	6-aryl-7-halo-imidazo[1,2-a]pyrimidines as anticancer agents This invention relates to methods for treating or inhibiting cancers in a mammal in need thereof, which comprises administering an effective amount of a 6-Aryl-7-halo-imidazo[1,2 -a]pyrimidine compound of the formula: or ph...	03/29/2011
7915229	Compositions containing piperacillin and tazobactam useful for injection An aminocarboxylic acid chelating agent, preferably EDTA, or a salt thereof has been found to be useful for inhibiting particulate formation in piperacillin/tazobactam parenteral combinations. The composition may also contain a buffer, preferably citrate, and option...	03/29/2011
7892563	Methods for treatment of severe acute respiratory syndrome (SARS) Compositions and methods for treating Severe Acute Respiratory Syndrome (SARS) are disclosed herein. Inhibitors of SARS-associated inflammatory cytokines are provided herein for use in treating SARS, including SARS-associated coronavirus (SARS-CoV) infection. Inhibi...	02/22/2011
7842187	Removal of bacterial endotoxin in a protein solution by immobilized metal affinity chromatography The present invention relates to the purification of polypeptides and the removal of endotoxin via immobilized metal affinity chromatography (IMAC). More specifically, the invention relates to methods for removing bacterial endotoxin in a protein solution. In specif...	11/30/2010
7785608	Immunogenic compositions for the prevention and treatment of meningococcal disease The present invention relates to Neisseria ORF2086 proteins, crossreactive immunogenic proteins which can be isolated from nesserial strains or prepared recombinantly, including immunogenic portions thereof, biological equivalents thereof, antibodies that imm...	08/31/2010
7741076	Production of the lipidated form of the peptidoglycan-associated lipoproteins of gram-negative bacteria The expression of the lipidated form of the peptidoglycan-associated protein (PAL) of gram-negative bacteria is achieved through the use of a plasmid containing a tightly regulated promoter. A bacterial host cell is transformed, transduced or transfected with such a...	06/22/2010
7687240	Process for increasing RSV surface glycoprotein yields using a mutant strain of RSV A process for producing isolated and purified respiratory syncytial virus (RSV) fusion (F) and attachment (G) glycoproteins in eukaryotic cell cultures infected with RSV cold-passaged, temperature-sensitive mutant subgroup A2 strain cpts-248/404 results in at least ...	03/30/2010
7666626	Mutants of the P4 protein of nontypable with reduced enzymatic activity A P4 variant protein that has reduced enzymatic activity and that induces antibody to wild-type P4 protein and/or has good bactericidal activity against non-typable H. influenzae (NTHi) is useful as an active component in an immunogenic composition for humans...	02/23/2010
7666433	Recombinant RSV strains with altered G protein The construction of recombinant respiratory syncytial virus (RSV) strains deleted of the region of G protein most likely to induce unwanted type 2 T cell responses in susceptible recipients is disclosed. Using reverse genetics, recombinant RSV strains were engineere...	02/23/2010
7658931	Mutant forms of cholera holotoxin as an adjuvant Mutant cholera holotoxins having single or double amino acid substitutions or insertions have reduced toxicity compared to the wild-type cholera holotoxin. The mutant cholera holotoxins are useful as adjuvants in antigenic compositions to enhance the immune response...	02/09/2010
7615229	Mutants of the P4 protein of nontypable with reduced enzymatic activity A P4 variant protein that has reduced enzymatic activity and that induces antibody to wild-type P4 protein and/or has good bactericidal activity against non-typable H. influenzae (NTHi) is useful as an active component in an immunogenic composition for humans...	11/10/2009
7611721	Adjuvant combination formulations The use of 3-O-deacylated monophosphoryl lipid A or monophosphoryl lipid A and derivatives and analogs thereof, in combination with a cytokine or lymphokine such as granulocyte macrophage colony stimulating factor or interleukin-12 is useful as an adjuvant combinati...	11/03/2009
7556940	Assembly of wild-type and chimeric influenza virus-like particles (VLPs) Influenza virus-like particles (VLPs) comprising the structural proteins HA, NA, M1 and M2 are described. VLPs are also generated containing M1 alone, as are VLPs with M1 and any one or two of HA, NA and M2. VLPs with HA from one influenza subtype and NA from a diff...	07/07/2009
7553634	Extraction of integral membrane proteins A process is described for extracting gram-negative integral membrane proteins from bacteria or bacterial host cells containing a recombinant vector by differential detergent tangential flow diafiltration. This process has several advantages over alternate processes...	06/30/2009
7541038	Fusogenic, self-propagating blebs as immunogenic compositions Self-propagating, fusogenic blebs are produced from cells infected with a population of Venezuelan Equine Encephalitis virus replicon particles (VRP). The self-propagating, fusogenic nature of the blebs is derived from expression of heterologous genes encoding viral...	06/02/2009
7527949	Polysaccharides of The invention is directed to immunogenic compositions comprising polysaccharides and polysaccharide-protein conjugates that are useful to induce or detect the production of antibodies specific for H. pylori. The invention is also directed to methods of purify...	05/05/2009
7524849	5-arylpyrimidines as anticancer agents This invention relates to certain 5-arylpyrimidine compounds or a pharmaceutically acceptable salt thereof, and compositions containing said compounds or a pharmaceutically acceptable salt thereof, wherein said compounds are anti-cancer agents useful for the treatme...	04/28/2009
7498312	Compositions containing piperacillin and tazobactam useful for injection An aminocarboxylic acid chelating agent, preferably EDTA, or a salt thereof has been found to be useful for inhibiting particulate formation in piperacillin/tazobactam parenteral combinations. The composition may also contain a buffer, preferably citrate, and option...	03/03/2009
7485667	Acetylenic aryl sulfonate hydroxamic acid tace and matrix metalloproteinase inhibitors Hydroxamic acids having the formula are useful in treating disease conditions mediated by TNF-□, such as rheumatoid arthritis, graft rejection, cachexia, inflammation, fever, insulin resistance, septic shock, congestive h...	02/03/2009
7452715	Production of the lipidated form of the peptidoglycan associated lipoproteins of gram-negative bacteria The expression of the lipidated form of the peptidoglycan-associated protein (PAL) of gram-negative bacteria is achieved through the use of a plasmid containing a tightly regulated promoter. A bacterial host cell is transformed, transduced or transfected with such a...	11/18/2008
7419982	Crystalline forms of 5-chloro-6-{2,6-difluoro-4-[3-(methylamino)propoxy]phenyl}-N-[(1S)-2,2,2-trifluoro-1-methylethyl][1,2,4]triazolo[1,5-a]pyrimidin-7-amine salts The present invention relates to crystalline forms of 5-chloro-6-{2,6-difluoro-4-[3-(methylamino)propoxy]phenyl}-N-[(1S)-2,2,2-trifluoro-1-methylethyl][1,2,4]triazolo[1,5-a]pyrimidin-7-amine salts; processes for the production thereof; pharmaceutical compositions th...	09/02/2008
7384640	Mutant cholera holotoxin as an adjuvant A mutant cholera holotoxin featuring a point mutation at amino acid 29 of the A subunit, wherein the glutamic acid residue is replaced by an amino acid other than aspartic acid, is useful as an adjuvant in an antigenic composition to enhance the immune response in a...	06/10/2008
7374751	QS-21 and IL-12 as an adjuvant combination Adjuvant compositions comprising an effective amount IL-12 and QS-21 are disclosed. Immunogenic, vaccine and pharmaceutical compositions comprising a mixture of antigen and an adjuvant composition comprising an effective amount of IL-12 and QS-21 are also disclosed....	05/20/2008
7361355	Mutant forms of cholera holotoxin as an adjuvant Mutant cholera holotoxins comprising a cholera toxin subunit A having single amino acid substitutions in the amino acid positions 16 or 72 or a double amino acid substitution in the amino acid positions 16 and 68 or 68 and 72 have reduced toxicity compared to the wi...	04/22/2008
RE40183	7-Substituted-9-substituted amino-6-demethyl-6-deoxytetracyclines The invention is drawn to 7-substituted-9-(substituted amino)-6-demethyl-6-deoxytetracycline compounds of the formula wherein R, X, R5 and R6 are defined in the specification. The compounds of the invention ...	03/25/2008
7344724	UspA1 and UspA2 antigens of The present invention discloses the existence of two novel proteins UspA1 and UspA2, and their respective genes uspA1 and uspA2. Each protein encompasses a region that is conserved between the two proteins and comprises an epitope that is recognized by the MAb 17C7....	03/18/2008
RE40086	Method for treating bacterial infection with novel 7-substituted-9-substituted amino 6-demethyl-6-deoxytetracyclines The disclosure is drawn to a method of using novel 7-substituted-9-(substituted amino)-6-demethyl-6-deoxytetracycline compounds to treat infections caused by a wide spectrum of bacterial organisms, including those which are resistant to tetracycline. ...	02/19/2008
7332174	Mutant forms of cholera holotoxin as an adjuvant Mutant cholera holotoxins having single or double amino acid substitutions or insertions have reduced toxicity compared to the wild-type cholera holotoxin. The mutant cholera holotoxins are useful as adjuvants in antigenic compositions to enhance the immune response...	02/19/2008
7316917	Production of bicyclic-heteroaryl-2-carboxylic acids by selective enzymatic hydrolysis of a mixture of positional esters The invention relates to an enzymatic process for the production of an intermediate, bicyclic-heteroaryl-2-carboxylic acid 7, of the formula wherein X and Y are defined in the specification and which are useful i...	01/08/2008
7297795	Process for preparation of 4-amino-3-quinolinecarbonitriles This invention discloses a process for the preparation of a 4-amino-3-quinolinecarbonitrile comprising combining an amine compound with a cyanoacetic acid and an acid catalyst to yield a cyanoacetamide; condensing the cyanoacetamide with an optionally up to tetra-su...	11/20/2007
7285555	6-aryl-7-halo-imidazo[1,2-a]pyrimidines as anticancer agents This invention relates to certain 6-aryl-7-halo-imidazo[1,2-a]pyrimidines or pharmaceutically acceptable salts thereof, and compositions containing said compounds or pharmaceutically acceptable salts thereof, wherein said compounds are anti-cancer agents useful for ...	10/23/2007
7285281	Mutant forms of cholera holotoxin as an adjuvant Mutant cholera holotoxins comprising a cholera toxin subunit A having single amino acid substitutions in the amino acid positions 16 or 72 or a double amino acid substitution in the amino acid positions 16 and 68 or 68 and 72 have reduced toxicity compared to the wi...	10/23/2007
7282496	Allenic aryl sulfonamide hydroxamic acids as matrix metalloproteinase and TACE inhibitors Compounds of the formula are useful in treating disease conditions mediated by TNF-α, such as rheumatoid arthritis, osteoarthritis, sepsis, AIDS, ulcerative colitis, multiple sclerosis, Crohn's disease, degenera...	10/16/2007
7276611	Process for synthesizing beta-lactamase inhibitor intermediates There is provided a process for the preparation of bicyclicheteroaryl carboxaldehydes having the structural Formula I where X and Y are defined in the specification The bicyclic heteroaryl carboxaldehydes are usefu...	10/02/2007
7238345	Recombinant microorganism expressing meningococcal class 1 outer membrane protein Outer-membrane vesicles, Class 1 outer membrane proteins of Neisseria meningitidis, fragments or oligopeptides containing epitopes of the Class I OMP can be used to immunize against meningococcal disease. ...	07/03/2007
7229983	4-substituted or unsubstituted-7-hydro-1,4-thiazepine-7-[bicyclic or tricyclic heteroaryl] substituted-3,6-dicarboxylic acid derivatives as β-lactamase inhibitors The present invention relates to novel, low molecular weight broad spectrum compounds in particular to a class of 4-substituted or unsubstituted-7-hydro-1,4-thiazepine-7-[bicyclic or tricyclic heteroaryl] substituted-3,6-dicarboxylic acid or their derivatives which ...	06/12/2007
7223854	Polynucleic acids isolated from a porcine reproductive and respiratory syndrome virus (PRRSV), proteins encoded by the polynucleic acids, vaccines based on the proteins and/or polynucleic acids, a method of protecting a pig from a PRRSV and a method of detecting a PRRSV The present invention provides a purified preparation containing a polynucleic acid encoding at least one polypeptide selected from the group consisting of proteins encoded by one or more open reading frames (ORF's) of an Iowa strain of porcine reproductive and resp...	05/29/2007
7223408	Human papillomavirus polypeptides and immunogenic compositions The present invention provides immunogenic and pharmaceutical compositions for the treatment and prevention of human papillomavirus (HPV)-associated cancers and in particular, cervical cancer. In particular, this invention relates to fusion proteins, and the nucleic...	05/29/2007

«First «Previous1 2 3 Next»Last»

PatentStorm

Quotables

PatentStorm News

Assignee: Wyeth Holdings Corporation